last updated: 04/2019
| Kinase-/ JAK -Inhibitoren |
| Jyseleca® (Filgotinib) |
| Olumiant® (Baricitinib) |
| Rinvoq® (Upadacitinib) |
| Xeljanz® (Tofacitinib) |
| Biologika |
| Cimzia® (Certolizumab Pegol) |
| Enbrel® (Etanercept) |
| Humira® (Adalimumab) |
| Kevzara® (Sarilumab ) |
| MabThera® (Rituximab) |
| Orencia® (Abatacept) |
| Remicade® (Infliximab) |
| RoActemra® (Tocilizumab) |
| Simponi® (Golimumab) |
| Biosimilar |
| Amgevita® (Adalimumab) |
| Benepali® (Etanercept) |
| Erelzi® (Etanercept) |
| Flixabi® (Infliximab) |
| Hulio® (Adalimumab) |
| Hyrimoz® (Adalimumab) |
| Idacio® (Adalimumab) |
| Imraldi® (Adalimumab) |
| Inflectra® (Infliximab) |
| Nepexto® (Etanercept) |
| Remsima® (Infliximab) |
| Rixathon® (Rituximab) |
| Ruxience® (Rituximab) |
| Zessly® (Infliximab) |
| Kontrollgruppe |
| Alle zugelassenen csDMARDs |
